JP2013536236A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536236A5
JP2013536236A5 JP2013526085A JP2013526085A JP2013536236A5 JP 2013536236 A5 JP2013536236 A5 JP 2013536236A5 JP 2013526085 A JP2013526085 A JP 2013526085A JP 2013526085 A JP2013526085 A JP 2013526085A JP 2013536236 A5 JP2013536236 A5 JP 2013536236A5
Authority
JP
Japan
Prior art keywords
use according
neoplastic disease
cancer
antibody
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013526085A
Other languages
English (en)
Japanese (ja)
Other versions
JP6241932B2 (ja
JP2013536236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/048747 external-priority patent/WO2012027324A2/en
Publication of JP2013536236A publication Critical patent/JP2013536236A/ja
Publication of JP2013536236A5 publication Critical patent/JP2013536236A5/ja
Priority to JP2016100753A priority Critical patent/JP6917681B2/ja
Application granted granted Critical
Publication of JP6241932B2 publication Critical patent/JP6241932B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013526085A 2010-08-23 2011-08-23 腫瘍性疾患のための治療 Active JP6241932B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2016100753A JP6917681B2 (ja) 2010-08-23 2016-05-19 腫瘍性疾患のための治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US37609710P 2010-08-23 2010-08-23
US61/376,097 2010-08-23
US40675910P 2010-10-26 2010-10-26
US61/406,759 2010-10-26
US41118310P 2010-11-08 2010-11-08
US61/411,183 2010-11-08
US201161480635P 2011-04-29 2011-04-29
US61/480,635 2011-04-29
PCT/US2011/048747 WO2012027324A2 (en) 2010-08-23 2011-08-23 Treatment for neoplastic diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016100753A Division JP6917681B2 (ja) 2010-08-23 2016-05-19 腫瘍性疾患のための治療

Publications (3)

Publication Number Publication Date
JP2013536236A JP2013536236A (ja) 2013-09-19
JP2013536236A5 true JP2013536236A5 (cg-RX-API-DMAC7.html) 2015-04-30
JP6241932B2 JP6241932B2 (ja) 2017-12-06

Family

ID=45594256

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013526085A Active JP6241932B2 (ja) 2010-08-23 2011-08-23 腫瘍性疾患のための治療
JP2016100753A Active JP6917681B2 (ja) 2010-08-23 2016-05-19 腫瘍性疾患のための治療
JP2019125907A Active JP7316120B2 (ja) 2010-08-23 2019-07-05 腫瘍性疾患のための治療
JP2021096528A Pending JP2021138750A (ja) 2010-08-23 2021-06-09 腫瘍性疾患のための治療
JP2025133305A Pending JP2025166117A (ja) 2010-08-23 2025-08-08 腫瘍性疾患のための治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016100753A Active JP6917681B2 (ja) 2010-08-23 2016-05-19 腫瘍性疾患のための治療
JP2019125907A Active JP7316120B2 (ja) 2010-08-23 2019-07-05 腫瘍性疾患のための治療
JP2021096528A Pending JP2021138750A (ja) 2010-08-23 2021-06-09 腫瘍性疾患のための治療
JP2025133305A Pending JP2025166117A (ja) 2010-08-23 2025-08-08 腫瘍性疾患のための治療

Country Status (17)

Country Link
US (3) US10294296B2 (cg-RX-API-DMAC7.html)
EP (3) EP2608808B1 (cg-RX-API-DMAC7.html)
JP (5) JP6241932B2 (cg-RX-API-DMAC7.html)
KR (7) KR102104296B1 (cg-RX-API-DMAC7.html)
CN (3) CN107281488B (cg-RX-API-DMAC7.html)
AU (1) AU2011293554B9 (cg-RX-API-DMAC7.html)
DK (1) DK2608808T3 (cg-RX-API-DMAC7.html)
ES (2) ES2856723T3 (cg-RX-API-DMAC7.html)
IL (2) IL262856B (cg-RX-API-DMAC7.html)
MX (2) MX388939B (cg-RX-API-DMAC7.html)
NZ (1) NZ607472A (cg-RX-API-DMAC7.html)
PH (2) PH12013500316A1 (cg-RX-API-DMAC7.html)
PT (1) PT2608808T (cg-RX-API-DMAC7.html)
RU (2) RU2013110030A (cg-RX-API-DMAC7.html)
SG (1) SG187853A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012027324A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201301420B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2582391T (pt) 2010-06-18 2019-01-11 Xbiotech Inc Tratamento da artrite
NZ607472A (en) 2010-08-23 2014-09-26 Xbiotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
DK2750709T3 (en) 2011-09-23 2018-12-03 Xbiotech Inc TREATMENT OF KAKEKSI
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
US20170260285A1 (en) * 2014-11-24 2017-09-14 University Of Iowa Research Foundation Methods for treating cancer
EP3582813A4 (en) 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) * 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2049342A1 (en) 1989-03-27 1990-09-28 Sally Bolmer Formulations for stabilizing of igm antibodies
US5407431A (en) 1989-07-11 1995-04-18 Med-Design Inc. Intravenous catheter insertion device with retractable needle
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1994008624A2 (en) 1992-10-14 1994-04-28 Sterling Winthrop Inc. Therapeutic and diagnostic imaging compositions and methods
DK0614984T4 (da) 1993-03-05 2010-12-20 Bayer Healthcare Llc Humane monoklonale anti-TNF-alfa-antistoffer
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6962702B2 (en) 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
EP1200479B1 (en) * 1999-08-09 2006-02-01 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
DE19943790C2 (de) 1999-09-13 2001-11-15 Ericsson Telefon Ab L M Verfahren und Vorrichtung zur Bestimmung eines Synchronisationsfehlers in einem Netzwerkknoten
US6380129B1 (en) 1999-11-02 2002-04-30 Richard J. Kraemer Enhanced materials for treatment of contamination
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US20020131954A1 (en) 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2007202323C1 (en) 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
WO2002033094A1 (en) 2000-10-19 2002-04-25 Kyowa Hakko Kogyo Co., Ltd. Antibody inhibiting vplf activity
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7348003B2 (en) * 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7273888B2 (en) 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
CN100522999C (zh) 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
WO2003074566A2 (en) 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
NZ538569A (en) 2002-09-06 2009-02-28 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Amf類を有効成分とする医薬製剤
WO2004100987A2 (en) 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
EP2239271A1 (en) 2003-06-13 2010-10-13 Biogen Idec MA Inc. Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
KR100493102B1 (ko) 2003-06-30 2005-06-02 삼성전자주식회사 서브 하우징 스토퍼를 구비하는 휴대용 단말기의 힌지 장치
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
WO2006036936A2 (en) 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
WO2006062779A2 (en) * 2004-12-09 2006-06-15 Centocor, Inc. Anti-integrin immunoconjugates, methods and uses
CN109187944A (zh) 2005-08-02 2019-01-11 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2623287A1 (en) 2005-09-28 2007-04-12 Cytos Biotechnology Ag Interleukin-1 conjugates and uses thereof
AU2007238677B2 (en) 2006-04-14 2011-03-10 Novartis Ag Use of IL-I antibodies for treating ophthalmic disorders
JP2009537507A (ja) 2006-05-15 2009-10-29 エクスバイオテク インコーポレーティッド アテローム性動脈硬化症に対して保護的な自己抗体を誘導するIL−1α免疫法
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN101472948A (zh) 2006-05-22 2009-07-01 埃克斯生物科技公司 使用抗IL-1α抗体治疗癌症
NZ597251A (en) 2006-05-30 2013-08-30 Genentech Inc Antibodies and immunoconjugates and uses therefor
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
WO2008082651A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
EP2265125B1 (en) 2008-04-15 2019-08-14 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
HUE029003T2 (en) 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
JP5976319B2 (ja) * 2008-09-12 2016-08-23 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 病原性単球の標的化
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
EP2391652A4 (en) 2009-01-29 2013-01-02 Abbott Lab IL-1 BINDING PROTEINS
FR2945396A1 (fr) * 2009-05-07 2010-11-12 St Microelectronics Grenoble 2 Procede et dispositif d'analyse de la propagation de transactions dans un reseau multi-protocoles d'un systeme sur puce
EP2488201A4 (en) 2009-10-15 2013-12-25 Abbvie Inc IL-1 BINDING PROTEINS
PL2575884T3 (pl) 2010-06-03 2018-12-31 Abbvie Biotechnology Ltd Zastosowania i kompozycje do leczenia ropni mnogich pach (HS)
PT2582391T (pt) 2010-06-18 2019-01-11 Xbiotech Inc Tratamento da artrite
NZ607472A (en) 2010-08-23 2014-09-26 Xbiotech Inc Treatment for neoplastic diseases
RU2013115927A (ru) 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
AU2012236106B2 (en) 2011-04-01 2016-12-08 Janssen Biotech, Inc. Treatment for dermatological pathologies
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。
DK2750709T3 (en) 2011-09-23 2018-12-03 Xbiotech Inc TREATMENT OF KAKEKSI
US20130195877A1 (en) 2012-01-31 2013-08-01 Xbiotech, Inc. Treatment of cachexia by targeting interleukin-1 beta
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
KR20150064091A (ko) 2012-10-04 2015-06-10 엑스바이오테크, 인크. 정신의학적 병태의 치료법
EP3524621A1 (en) 2012-10-04 2019-08-14 XBiotech, Inc Treating vascular disease and complications thereof
EP2975054A4 (en) 2013-03-12 2016-11-23 Zenyaku Kogyo Kk ANTIBODIES TO STAPHYLOKOKEN, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
US20150024031A1 (en) 2013-07-17 2015-01-22 Baxter International Inc. Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent
BR112016028043B1 (pt) 2014-06-03 2023-12-12 Xbiotech Inc Composição farmacêutica e anticorpo monoclonal
EP3582813A4 (en) 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS

Similar Documents

Publication Publication Date Title
JP2013536236A5 (cg-RX-API-DMAC7.html)
Levy et al. Targeting autophagy during cancer therapy to improve clinical outcomes
IL214255B (en) Use of antibodies for the preparation of drugs for the treatment of cancer associated with tumor antigen and methods for diagnosing cancer associated with tumor antigen
WO2015049688A3 (en) Patient-specific immunotherapy for treating heterogeneous tumors
NZ719368A (en) Combination therapy of antibodies against human csf-1r and uses thereof
NZ601580A (en) Therapeutic methods using anti-cd200 antibodies
NZ703481A (en) Cd37-binding molecules and immunoconjugates thereof
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
JP2014512354A5 (cg-RX-API-DMAC7.html)
JP2014508752A5 (cg-RX-API-DMAC7.html)
JP2014509659A5 (cg-RX-API-DMAC7.html)
EP3064509A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
ZA201209289B (en) Urea derivatives and their therapeutic use in the treatment of,inter alia,diseases of the respiratory tract
IN2015DN00450A (cg-RX-API-DMAC7.html)
JP2016519107A5 (cg-RX-API-DMAC7.html)
NZ741615A (en) Treatment of brain cancer
RU2015145997A (ru) Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат
TWD162792S (zh) 粒子線治療機器用放射線照射器
RU2013110030A (ru) Лечение неопластических заболеваний
EA201691385A1 (ru) Комбинированная терапия рака
JP2015531397A5 (cg-RX-API-DMAC7.html)
JP2013544892A5 (cg-RX-API-DMAC7.html)
TWD164871S (zh) 粒子線治療機器用放射線照射器
NZ625758A (en) Method for treating breast cancer
Howell Second primary cancers and cardiovascular disease after radiation therapy. NCRP report no. 170